Treatment Clinical Trials for Nonmelanoma Skin Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are for nonmelanoma skin cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 47
1 2 Next >

  • NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

    This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1170 locations

  • Nivolumab and Ipilimumab in Treating Patients with Rare Tumors

    This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 732 locations

  • Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

    To estimate the clinical benefit of REGN2810 monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC) (Groups 1 and 3) or with unresectable locally advanced CSCC (Group 2), as measured by overall response rate (ORR), according to central review.
    Location: 20 locations

  • An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors

    The purpose of this study to investigate the safety and effectiveness of Nivolumab, and Nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the following types of tumors: - Anal canal cancer - Cervical cancer - Epstein Barr Virus (EBV) positive gastric cancer - HPV positive and negative squamous cell cancer of the head and neck (SCCHN) - Merkel Cell Cancer - Nasopharyngeal cancer (NPC) - Penile cancer - Vaginal and vulvar cancer
    Location: 11 locations

  • Electronic Skin Surface Brachytherapy in Treating Older Patients with Newly Diagnosed Early Stage Basal Cell or Squamous Cell Skin Cancer

    This pilot clinical trial studies how well electronic skin surface brachytherapy (ESSB) works in treating older patients with newly diagnosed early stage basal cell or squamous cell skin cancer. ESSB is a type of radiation therapy that uses skin surface applicators to place electronic radiation sources to treat skin cancer. Skin surface applicators are round, smooth disks that are attached to the radiation treatment machine, and give off the radiation for treatment. ESSB may allow the tumor to be treated while underlying healthy tissues are not harmed by radiation.
    Location: 7 locations

  • Proton Beam or Photon-Based Intensity-Modulated Radiation Therapy in Treating Patients with Salivary Gland Cancer, Skin Cancer, or Melanoma

    This randomized phase II trial studies the side effects of proton beam or photon-based intensity-modulated radiation therapy in treating patients with salivary gland cancer, skin cancer, or melanoma. Proton beam radiation therapy uses tiny charged particles to deliver radiation directly to the tumor and may cause less damage to normal tissue. Intensity-modulated or photon beam radiation therapy uses high-energy x-ray beams shaped to treat the tumor and may also cause less damage to normal tissue. It is not yet known if proton beam radiation therapy is more effective than photon-based intensity-modulated radiation therapy in treating patients with salivary gland cancer, skin cancer, or melanoma.
    Location: 6 locations

  • ALT-803 in Treating Patients with Advanced Cancer

    This phase I trial studies the side effects and best dose of superagonist interleukin-15: interleukin-15 receptor alpha Su / Fc fusion complex ALT-803 (ALT-803) in treating patients with melanoma cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Biological therapies, such as ALT-803, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing.
    Location: 8 locations

  • A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

    This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm.
    Location: 6 locations

  • Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)

    This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in subjects with metastatic Merkel cell carcinoma (MCC).
    Location: 5 locations

  • PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

    Protocol PEN-221-001 is an open-label, multicenter Phase 1 / 2a study evaluating PEN-221 in patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of the lung.
    Location: 6 locations

  • Radiation Therapy and Pembrolizumab in Treating Patients with Head and Neck Squamous Cell Carcinoma That Is Recurrent or Cannot Be Removed by Surgery

    This phase II trial studies how well radiation therapy and pembrolizumab work in treating patients with head and neck squamous cell carcinoma that has come back or cannot be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving radiation therapy together with pembrolizumab may kill more tumor cells.
    Location: 4 locations

  • Radiation Therapy and Vismodegib in Treating Patients With Locally Advanced Head and Neck Cancer

    This phase II trial studies how well radiation therapy and vismodegib work in treating patients with locally advanced head and neck cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as vismodegib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with chemotherapy may kill more tumor cells.
    Location: 3 locations

  • Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease

    This phase II trial studies how well stereotactic radiosurgery works in treating patients with cancer that has come back and has spread to 5 or fewer places in the body (oligometastatic disease). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
    Location: 3 locations

  • Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease

    This phase II trial studies how well stereotactic radiosurgery works in treating patients with cancer that has spread to 5 or fewer places in the body and involves 3 or fewer organs (oligometastatic disease). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
    Location: 3 locations

  • Phase 1 / 2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers

    This is a Phase 1 / 2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients with NTRK fusion cancers treated with prior TRK inhibition or non-fusion NTRK altered cancers regardless of prior kinase inhibitor treatment.
    Location: 2 locations

  • PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

    The primary objective is to estimate the overall response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with REGN2810 as a monotherapy
    Location: 5 locations

  • Phase 1 / 2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

    The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
    Location: 5 locations

  • Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

    This is a multicenter, open-label, phase 1 study that is being done to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts. Part 1 is the Dose Escalation phase and Part 2 is the Dose Expansion phase. The purpose of this study is to characterize the safety profile of TTI-621 and to determine the optimal dose and delivery schedule of TTI-621.
    Location: 3 locations

  • Talimogene Laherparepvec with or without Hypofractionated Radiation Therapy in Treating Patients with Metastatic Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

    This phase II trial studies the side effects of talimogene laherparepvec and to see how well it works with or without hypofractionated radiation therapy in treating patients with skin melanoma, Merkel cell carcinoma, or other solid tumors that have spread to places not suitable for surgical removal. Drugs used in the immunotherapy, such as talimogene laherparepvec, may stimulate the body's immune system to fight tumor cells. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. It is not yet known if giving talimogene laherparepvec with or without hypofractionated radiation therapy will work better in treating patients with cutaneous melanoma, Merkel cell carcinoma, or solid tumors.
    Location: 2 locations

  • Docetaxel, Cisplatin, and Cetuximab in Treating Patients with Metastatic or Relapsed Head and Neck Cancer

    This phase II trial studies how well docetaxel, cisplatin, and cetuximab work in treating patients with squamous cell carcinoma of the head and neck that has spread to the primary site to other places in the body or has come back after a period of improvement. Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as cetuximab, interfere with the ability of tumor cells to grow and spread. Giving docetaxel together with cisplatin and cetuximab may be an effective treatment for head and neck cancer.
    Location: 2 locations

  • Cisplatin or Carboplatin and Etoposide With or Without Vandetanib in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer or High-Grade or Poorly Undifferentiated Neuroendocrine Cancer

    This randomized phase II trial studies how well cisplatin or carboplatin and etoposide with or without vandetanib works in treating patients with previously untreated extensive stage small cell lung cancer or high-grade or poorly differentiated neuroendocrine cancer. Drugs used in chemotherapy, such as cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving cisplatin or carboplatin and etoposide is more effective with or without vandetanib in treating small cell lung cancer or neuroendocrine cancer.
    Location: 2 locations

  • A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects With Advanced Solid Tumors

    The primary purpose of this study is to evaluate the tolerability and safety profile of ASP8374 in participants with locally advanced (unresectable) or metastatic solid tumors. Also primary purpose is to characterize the pharmacokinetic profile of ASP8374 and to determine the recommended Phase 2 dose (RP2D) of ASP8374. The secondary purpose of this study is to evaluate the anti-tumor effect of ASP8374.
    Location: Columbia University / Herbert Irving Cancer Center, New York, New York

  • MAGE-A4ᶜ¹º³²T for Multi-Tumor

    This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, or gastric tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Pembrolizumab and Cetuximab in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    This phase II trial studies how well pembrolizumab and cetuximab work in treating patients with head and neck squamous cell carcinoma that has come back or spread to other places in the body. Monoclonal antibodies, such as pembrolizumab and cetuximab, may interfere with the ability of tumor cells to grow and spread.
    Location: 4 locations

  • Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors

    This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Monoclonal antibodies, such as atezolizumab and bevacizumab block tumor growth in different ways by targeting certain cells.
    Location: M D Anderson Cancer Center, Houston, Texas


1 2 Next >